Abela M, Lentini F, Gatt A, Felice Malta Medial School Conference 2012

Slides:

Advertisements

Similar presentations

Tables presmedic.com (917)

Advertisements

A ggrastat- Phase of the AGGRASTAT to ZOCOR (A to Z) Trial Comparison of the safety and efficacy of unfractionated heparin versus enoxaparin in combination.

Treatment of Acute Coronary Syndrome with ST elevation ESC guidelines 2008 Dr. David Tran A&E dept. FVH 22/12/09.

Bree Collaborative Cardiology Report: Appropriateness of Percutaneous Cardiac Interventions (PCI) Bree Collaborative Meeting November 30, 2012.

Implementation of ESC/ACC Definition of Myocardial Infarction in Contemporary, Large RCTs: A Systematic Review Sergio Leonardi, L. Kristin Newby, E. Magnus.

“Adjunctive Therapy” Non ST segment elevation ACS Dr M R Thomas King’s College Hospital. Advanced Angioplasty 2002.

Development of Clinical Pathways to Streamline Care for Patients Presenting with Suspected Cardiac Chest Pain Background The National Heart Foundation.

USE OF CITRATED CLOTTING TIME IN MONITORING ENOXAPARIN LEVEL DURING CONTEMPORARY PERCUTANEOUS CORONARY INTERVENTION IN ACUTE CORONARY SYNDROMES B.Y.C.

TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.

Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.

Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) Presented.

Acute Coronary Syndromes SIGN 93. MINAP Mortality after Acute Coronary Syndromes Cumulative: 13.6% Blue 10.6% Green 11.6% Red.

Pharmacotherapy in acute coronary syndromes Perspective from first line and regional hospitals in Czech Republic Cardionale, Petr Jansky.

Acute Coronary Syndromes in West Hertfordshire Masood Khan.

The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.

GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.

? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.

Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.

NICE-3 National Investigators Collaborating on Enoxaparin XXII nd Congress of the European Society of Cardiology August 30, 2000 Amsterdam, The Netherlands.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacologic plaque passivation for the reduction.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Josephine Mak Waikato Cardiothoracic Unit Journal Club

A Clinical profile of patients enrolled in the Pakistan ACS registry

Prof. Dr. med. Sigmund Silber Cardiology Practice and Hospital

Volume 81, Issue 10, Pages (October 2010)

Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.

Figure 1 The flowchart depicts the total number of procedures in the Western Denmark Heart Registry (WDHR) and the exclusion of patients; NPR, National.

Initial pharmacotherapy for ST-segment elevation myocardial infarction

Initial pharmacotherapy for ST-segment elevation myocardial infarction

The European Society of Cardiology Presented by Dr. Saman Rasoul

Characteristics of High and Low Molecular Weight Heparin Chains

CHD-related catheterization

Adjusted odds ratio 95% CI Diagnostic angiography PCI CABG

Contemporary Diagnosis and Management of Unstable Angina

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Glenn N. Levine et al. JACC 2016;68:

by Nadine Martel, James Lee, and Philip S. Wells

European Society of Cardiology 2003

The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,

Section F: Clinical guidelines

Recent Temporal Trends in the Presentation, Management, and Outcome of Women Hospitalized with Acute Coronary Syndromes Avi Sabbag, MD, Shlomi Matetzky,

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Cost-Effectiveness of Introducing Point-of-Care Test for Detection of Level of Glycogen Phosphorylase in Early Diagnostic Algorithm of Acute Coronary.

Invasive versus conservative treatment in unstable coronary syndromes

% Heparin + GPI IIb/IIIa Bivalirudin +

The European Society of Cardiology Presented by RJ De Winter

Attributable Cost and Length of Stay for Patients with Enoxaparin-Associated Bleeding Surasak Saokaew, PharmD, Narinee Khaisombat, MSc, Nathorn Chaiyakunapruk,

Category: PCI Research

One-year clinical outcomes in older patients with non-ST elevation acute coronary syndrome undergoing coronary angiography: An analysis of the ICON1 study

The recommended approach to patients with chronic obstructive pulmonary disease (COPD) presenting with dyspnoea. The recommended approach to patients with.

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Clinical Trial Commentary

The use of functional tests and planned coronary angiography after percutaneous coronary revascularization in clinical practice.Results from the AFTER.

Fig. 3. Determining factors of the proportion of class C in the hospital. (A) Relationship between the proportion of class C cases and the number of PCIs.

Figure 9 Management of atrial fibrillation

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Comparison of radial versus femoral access in patients undergoing invasive management for acute coronary syndromes: evidence from a systematic review and.

Flow Diagram of the Trial Selection Process

Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter

FRISC Trial Placebo control, double blind Lancet 347:561,1996

Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 2: ST-Segment Elevation.

Kaplan–Meyer survival curve of 1313 patients following primary PCI

Leslee J. Shaw et al. JIMG 2010;3:

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Study flow chart and diagnosis at discharge from ED

Presentation transcript:

Abela M, Lentini F, Gatt A, Felice Malta Medial School Conference 2012 Low Molecular Weight Heparin in Non-ST Acute Coronary Syndrome and Unstable Angina – Auditing the learning curve and future implications at Mater Dei Hospital Abela M, Lentini F, Gatt A, Felice Malta Medial School Conference 2012

Aim and Methodology To assess the regime administration of low molecular weight heparin (LMWH) during urgent percutaneous coronary intervention (PCI) in patients with Non-ST Acute Coronary Syndrome and Unstable Angina from January to July 2011. The list was compiled using the Catheterisation Lab’s database and the relative case notes were reviewed. Results were compared to the recommendations of the European Society of Cardiology (ESC) and Summary of Product Characteristics (SPC)

Results

Action Plan Proforma to be used when Enoxaparin is the drug of choice in NST-ACS and Unstable Angina